Tech Company Financing Transactions
Superluminal Medicines Funding Round
BVF Partners, Catalio Capital Management and Cooley invested in a $60 million Series B venture round for Superluminal Medicines. The financing was announced by the company on 9/3/2026.
Transaction Overview
Company Name
Announced On
9/3/2026
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support advancing its lead program for rare genetic forms of obesity and hypothalamic obesity, advance additional pipeline programs, and further expand its portfolio of new small-molecule GPCR-targeted therapies for endocrine and cardiometabolic diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
200 Berkeley St, 18th Floor
Boston, MA 02116
USA
Boston, MA 02116
USA
Phone
Undisclosed
Website
Email Address
Overview
Superluminal Medicines is a generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. The company's platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Cony D'Cruz
Browse more venture capital transactions:
Prev: 9/3/2026: YoLearn.ai venture capital transaction
Next: 9/3/2026: Guardio venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs